Glepaglutide

Drug Profile

Glepaglutide

Alternative Names: ZP 1848

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zealand Pharma
  • Class Glucagon-like peptides
  • Mechanism of Action Glucagon-like peptide 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Short bowel syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Short bowel syndrome
  • Discontinued Inflammatory bowel diseases

Most Recent Events

  • 14 Nov 2017 Zealand Pharma completes enrolment in its phase I trial for Short bowel syndrome (in volunteers) in USA (NCT03279302)
  • 24 Oct 2017 Glepaglutide receives Orphan Drug status for Short bowel syndrome in USA
  • 24 Oct 2017 Updated efficacy data from a phase II trial in Short bowel syndrome released by Zealand Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top